Last reviewed · How we verify
Gemcitabin
At a glance
| Generic name | Gemcitabin |
|---|---|
| Also known as | Gem, Gemzar |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Target | UMP-CMP kinase, Deoxycytidine kinase, Ribonucleoside-diphosphate reductase large subunit |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Adenocarcinoma of pancreas
- Malignant tumor of ovary
- Metastatic Breast Carcinoma
- Non-small cell lung cancer
Common side effects
- Nausea and Vomiting
- Anemia
- Increased ALT
- Increased AST
- Neutropenia
- Increased Alkaline Phosphatase
- Proteinuria
- Fever
- Hematuria
- Rash
- Thrombocytopenia
- Dyspnea
Serious adverse events
- Neutropenia Grade 3/4
- Nausea/Vomiting Grade 3/4
- Increased ALT Grade 3/4
- Increased Alkaline Phosphatase Grade 3/4
- Anemia Grade 3/4
- Increased AST Grade 3/4
- Thrombocytopenia Grade 3/4
- Myocardial Infarction
- Cerebrovascular Accident
- Dyspnea Grade 3/4
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (PHASE2)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |